BFH772 (VEGFR2 inhibitor): Technical Guidance for Selective Angiogenesis Inhibition

What This Product Solves

BFH772 is a small-molecule VEGFR2 inhibitor (CAS 890128-81-1) that provides precise, high-affinity inhibition of the VEGFR2 kinase. This selectivity enables researchers to dissect VEGFR2-mediated angiogenic signaling with minimal off-target effects on related kinases. Its application is especially relevant in tumor angiogenesis research and other studies requiring targeted disruption of VEGFR2-driven pathways (BFH772 (VEGFR2 inhibitor)). BFH772 is not appropriate for protocols dependent on water-soluble compounds or where broad-spectrum kinase inhibition is required, due to its solvent compatibility and selectivity profile (source: internal article).

Protocol Parameters

• in vitro kinase inhibition assay | IC₅₀ = 3 nM | precise VEGFR2 pathway inhibition | enables low-dose, high-specificity interrogation of VEGFR2 signaling | product_spec
• compound solubility determination | ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol; insoluble in water | suitable for DMSO/ethanol-based dissolution workflows | ensures reproducible compound delivery and avoids precipitation | product_spec
• animal tumor model studies (oral dosing) | significant inhibition of tumor growth and angiogenesis (qualitative) | effective in preclinical models for anti-angiogenic research | supports utility as an oral VEGFR2 inhibitor for tumor angiogenesis research | product_spec
• storage protocol | -20°C; avoid long-term storage of solutions | all research workflows | maintains compound integrity and prevents degradation | product_spec

Workflow Setup and QC Checklist

To maximize experimental reliability with BFH772, implement the following workflow best practices:

1. Compound Handling: Prepare stock solutions in DMSO or ethanol at concentrations not exceeding solubility limits (≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol). Avoid using aqueous solutions due to insolubility (source: internal article).
2. Aliquoting and Storage: Store dry compound at -20°C. Aliquot stock solutions to avoid multiple freeze–thaw cycles, and use fresh dilutions for each experiment. Discard any solution stored long-term, as stability is not guaranteed.
3. Assay Controls: Include vehicle (solvent-only) controls to distinguish compound effects from solvent artifacts.
4. Purity Verification: Check the supplied certificate of analysis (purity ≥96%) to confirm quality prior to use. Retain batch QC and safety data sheets for compliance documentation.
5. Documentation: Record lot numbers, preparation dates, and solution concentrations in lab notebooks for traceability.

Common Failure Modes and Fixes

• Precipitation in Assay Wells: If visible precipitate forms, verify that the BFH772 stock was fully dissolved in DMSO or ethanol prior to dilution. Reduce compound concentration or increase DMSO/ethanol carrier within protocol limits to ensure solubility.
• Lack of Inhibition: Confirm accurate dosing and that the compound is within its effective concentration range (IC₅₀ = 3 nM for VEGFR2). Exclude loss of potency due to improper storage or repeated freeze–thaw cycles.
• Non-specific Effects: Use proper vehicle controls, and confirm that observed effects are not due to high solvent concentrations or off-target kinase inhibition (noting that BFH772 has ~500-fold selectivity over FLK-1, FLT-1, FLT-4, and ~40-fold over B-RAF, RET, TIE-2; source: product_spec).
• Batch Variability: Reference the certificate of analysis and QC data for each batch. If inconsistencies arise, consult APExBIO technical support for lot-specific guidance.

Scope and Limitations

BFH772 is most effective in research contexts requiring specific VEGFR2 inhibition—such as studies of tumor angiogenesis or targeted interrogation of the VEGFR2 signaling pathway. The compound’s high selectivity enables mechanistic clarity in kinase-focused workflows. However, its insolubility in water precludes use in aqueous-only systems or high-throughput screens not compatible with organic solvents. Researchers requiring broad-spectrum kinase inhibition or alternative solubility profiles should select different agents. For additional technical recommendations and detailed protocol guidelines, see this internal article, which reviews practical use of BFH772 in selective angiogenesis workflows.

Conclusion

BFH772 offers researchers a precise tool for selective inhibition of VEGFR2 in angiogenesis and tumor model studies, provided its solvent compatibility and storage guidelines are strictly followed. For detailed product specifications, refer to the BFH772 (VEGFR2 inhibitor) product page. By adhering to best practices in dissolution, storage, assay setup, and QC, laboratories can achieve reproducible, high-specificity inhibition of VEGFR2-driven pathways. When used as recommended, BFH772 facilitates rigorous investigation of angiogenic mechanisms in preclinical research.